Key Findings:  For years, its activity has been enigmatic for gastroenterologists and pharmacologists, but now it is evident that this compound may interact at extra-cannabinoid system receptor sites, such as peroxisome proliferator-activated receptor-gamma. This strategic interaction makes CBD as a potential candidate for the development of a new class of anti-IBD drugs.
Type of Study:  Meta-analysis
Study Result:  Positive
Study Location(s):  Italy
Year of Pub:  2013
Cannabinoids Studied:  Cannabidiol (CBD)
Phytocannabinoid Source:  Not Applicable
Chemotype:  Chemotype III
Receptors Studied:  PPARs